Review of applications will commence immediately.
The Vall d´Hebron Institute of Oncology´s (VHIO) Tumor Immunology and Immunotherapy Group, headed by Dr. Alena Gros, is currently recruiting for a Scientific Laboratory Technician to validate the expansion of tumor-infiltrating lymphocytes (TILs) for patient treatment in good manufacturing practice conditions. The successful candidate will work between Dr. Gros’ lab (VHIO) and the Blood and Tissue Bank (Poble Nou, Barcelona) and, working with team at the Blood and Tissue Bank, will support the expansion of TILs in GMP conditions and contribute to the generation of TIL products for the treatment of patients.
A very organized, motivated, team-oriented individual, who is highly skilled in cell/tissue culture and processing. The ideal candidate should be familiar with ELISA, ELISpot, flow-cytometry, and comfortable working with human blood and tissues. Previous experience working in cGMP conditions is preferred.
Candidates must submit a curriculum vitae and letter of intent addressed to Dr. Alena Gros using the form below or via email to: email@example.com, adding “Ref. 06/2019” in the subject line.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: http://www.vhio.net.